



Jonathan S. Berek, MD, MMSc

Laurie Kraus Lacob Professor

Obstetrics & Gynecology - Gynecologic Oncology

CLINICAL OFFICE (PRIMARY)

- **Stanford Women's Cancer Center**

900 Blake Wilbur Dr

1st Fl MC 5854

Palo Alto, CA 94304

Tel (650) 498-6004 **Fax** (650) 498-7237

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Dustyne Schulze - Administrative Assistant

Email dustynes@stanford.edu

Tel 650-497-0387

Bio

BIO

Laurie Kraus Lacob Professor

Stanford University School of Medicine

Director, Stanford Women's Cancer Center

Senior Advisor, Stanford Cancer Institute

Executive Director, Stanford Health Communication Initiative

Director, MedArts Films

Stanford Center for Health Education

Stanford University

CLINICAL FOCUS

- Cancer > Gynecologic Cancer
- Gynecologic Cancers - Gynecologic Oncology
- Ovarian Cancer
- Uterine Cancer
- Uterine Cervical Cancer
- Vaginal Cancer
- Vulvar Cancer
- Trophoblastic Neoplasms
- Pelvic Reconstructive Surgery
- Neovagina

- Obstetrics and Gynecology

ACADEMIC APPOINTMENTS

- Professor, Obstetrics & Gynecology - Gynecologic Oncology
- Member, Bio-X
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Executive Director, Stanford Health Communication Initiative, Stanford Center for Health Education, Stanford University, (2018- present)
- Senior Advisor, Stanford Cancer Institute, (2016- present)
- Director, Stanford Health Care Communication Program, (2015-2018)
- Laurie Kraus Lacob Professor, Stanford University School of Medicine, (2012- present)
- Director, Stanford Women's Cancer Center, Stanford Cancer Institute, (2008- present)
- Chair, Department of Obstetrics and Gynecology, Stanford University School of Medicine, (2005-2017)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Chair, FIGO Women's Cancer Committee, International Federation of Obstetrics & Gynecology (FIGO) (2021 - present)
- International Committee, American Society of Clinical Oncology (2017 - present)
- Executive Committee, Gynecologic Cancer InterGroup (2017 - present)
- Executive Committee, Cervical Cancer Research Network (2017 - present)
- Chair, Education Committee, Gynecologic Cancer InterGroup (2017 - 2021)
- Gynecologic Oncology Committee, Cancer Staging, FIGO (2016 - 2021)

PROFESSIONAL EDUCATION

- Fellowship: UCLA Medical Center Obstetrics and Gynecology Fellowships (1981) CA
- Residency: Harvard Medical School (1979) MA
- Internship: Harvard Medical School (1976) MA
- Board Certification: Gynecologic Oncology, American Board of Obstetrics and Gynecology (1983)
- Board Certification: Obstetrics and Gynecology, American Board of Obstetrics and Gynecology (1982)
- Medical Education: Johns Hopkins University School of Medicine (1973) MD
- Biomedical Sciences, Brown University , MMS (1973)

COMMUNITY AND INTERNATIONAL WORK

- Past President, Council of University Chairs of Obstetrics and Gynecology (CUCOG)
- Past President, International Gynecologic Cancer Society, International

Research & Scholarship

CLINICAL TRIALS

- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples, Recruiting
- A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer, Not Recruiting
- A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer, Not Recruiting
- A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004), Not Recruiting

- A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma, Not Recruiting
- A Study of CDX-1127 (Varilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers, Not Recruiting
- A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma, Not Recruiting
- A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies, Not Recruiting
- A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens, Not Recruiting
- Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer, Not Recruiting
- Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer, Not Recruiting
- Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer, Not Recruiting
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer, Not Recruiting
- Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer, Not Recruiting
- Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer, Not Recruiting
- Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer, Not Recruiting
- Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer, Not Recruiting
- Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment, Not Recruiting
- Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer, Not Recruiting
- Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse, Not Recruiting
- Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients, Not Recruiting
- Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO], Not Recruiting
- Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy, Not Recruiting
- Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy., Not Recruiting
- OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission, Not Recruiting
- Ovarian Cancer Vaccine for Patients in Remission, Not Recruiting
- Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer, Not Recruiting
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer, Not Recruiting
- Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer, Not Recruiting
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer, Not Recruiting
- Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer, Not Recruiting
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer, Not Recruiting
- Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer, Not Recruiting
- Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer, Not Recruiting
- Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer, Not Recruiting
- Safety and Efficacy of CRS-207 With Epcadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer, Not Recruiting

- Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy, Not Recruiting
- Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors, Not Recruiting
- Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer, Not Recruiting
- Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED), Not Recruiting
- Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer, Not Recruiting
- Study of FP-1039 in Subjects With Endometrial Cancers, Not Recruiting
- Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites, Not Recruiting
- Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer, Not Recruiting
- Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer, Not Recruiting
- Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer, Not Recruiting
- Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus, Not Recruiting
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer, Not Recruiting
- TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer, Not Recruiting
- Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer, Not Recruiting
- Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Not Recruiting
- VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Not Recruiting
- Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries, Not Recruiting

Publications

PUBLICATIONS

- **Cancer of the ovary, fallopian tube, and peritoneum.** *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*
Berek, J. S., Kehoe, S. T., Kumar, L., Friedlander, M.
2018; 143 Suppl 2: 59–78
- **Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation"** *JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY*
Parker, W. H., Berek, J. S., Pritts, E. A., Olive, D., Chalas, E., Clarke-Pearson, D.
2018; 25 (6): 1113
- **Occult Gynecologic Cancer in Women Undergoing Hysterectomy or Myomectomy for Benign Indications.** *Obstetrics and gynecology*
Chalas, E., Clarke-Pearson, D., Berek, J. S.
2018; 132 (2): 519
- **Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial** *LANCET ONCOLOGY*
Oza, A. M., Matulonis, U. A., Malander, S., Hudgens, S., Sehoul, J., del Campo, J. M., Berton-Rigaud, D., Banerjee, S., Scambia, G., Berek, J. S., Lund, B., Tinker, A. V., Hilpert, et al
2018; 19 (8): 1117–25
- **30 years of Current Opinion in Obstetrics and Gynecology: looking back and looking forward** *CURRENT OPINION IN OBSTETRICS & GYNECOLOGY*
Berek, J. S., Fairbairn, S.
2018; 30 (2): 99
- **Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry** *CELL REPORTS*

- Gonzalez, V. D., Samusik, N., Chen, T. J., Savig, E. S., Aghaeepour, N., Quigley, D. A., Huang, Y., Giangarra, V., Borowsky, A. D., Hubbard, N. E., Chen, S., Han, G., Ashworth, et al
2018; 22 (7): 1875–88
- **Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)** *GYNECOLOGIC ONCOLOGY*
Roncolato, F. T., Berton-Rigaud, D., O'Connell, R., Lanceley, A., Sehoul, J., Buizen, L., Okamoto, A., Aotani, E., Lorusso, D., Donnellan, P., Oza, A., Avall-Lundqvist, E., Berek, et al
2018; 148 (1): 36–41
 - **Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer** *QUALITY OF LIFE RESEARCH*
King, M. T., Stockler, M. R., O'Connell, R. L., Buizen, L., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Bryce, J., Donnellan, P., Oza, A., Avall-Lundqvist, et al
2018; 27 (1): 59–74
 - **Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study** *ONCOLOGIST*
Roncolato, F. T., Joly, F., O'Connell, R., Lanceley, A., Hilpert, F., Buizen, L., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P., Oza, A., Avall-Lundqvist, E., Berek, et al
2017; 22 (9): 1117–24
 - **Reply to B.O. Anderson et al.** *Journal of global oncology*
Chuang, L. T., El Saghir, N. S., Temin, S., Berek, J. S.
2017; 3 (1): 89–92
 - **5th Ovarian Cancer Consensus Conference: Individualized Therapy and Patient Factors.** *Annals of oncology*
McGee, J., Bookman, M., Harter, P., Marth, C., McNeish, I., Moore, K. N., Poveda, A., Hilpert, F., Hasegawa, K., Bacon, M., Gatsonis, C., Brand, A., Kridelka, et al
2017
 - **Immunotherapy in ovarian cancer** *CURRENT PROBLEMS IN CANCER*
Krishnan, V., Berek, J. S., Dorigo, O.
2017; 41 (1): 48-63
 - **Salpingo-Oophorectomy at the Time of Benign Hysterectomy: A Systematic Review** *OBSTETRICS AND GYNECOLOGY*
Parker, W. H., Broder, M. S., Berek, J. S., Manson, J. E.
2017; 129 (1): 202
 - **Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer** *NEW ENGLAND JOURNAL OF MEDICINE*
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., Ben-Baruch, N. E., Marth, C., Madry, et al
2016; 375 (22): 2154-2164
 - **Immunotherapy in ovarian cancer.** *Current problems in cancer*
Krishnan, V., Berek, J. S., Dorigo, O.
2016
 - **Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline.** *Journal of global oncology*
Chuang, L. T., Temin, S., Camacho, R., Duenas-Gonzalez, A., Feldman, S., Gultekin, M., Gupta, V., Horton, S., Jacob, G., Kidd, E. A., Lishimpi, K., Nakisige, C., Nam, et al
2016; 2 (5): 311–40
 - **Management and Care of Women With Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline** *JOURNAL OF CLINICAL ONCOLOGY*
Chuang, L. T., Feldman, S., Nakisige, C., Temin, S., Berek, J. S.
2016; 34 (27): 3354–U338
 - **Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo** *ONCOTARGET*
Park, S., Chung, Y. M., Ma, J., Yang, Q., Berek, J. S., Hu, M. C.

2016; 7 (27): 42110-42125

- **Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary** *JOURNAL OF ONCOLOGY PRACTICE*
Chuang, L. T., Temin, S., Berek, J. S.
2016; 12 (7): 693-+
- **Can Arts and Communication Programs Improve Physician Wellness and Mitigate Physician Suicide?** *JOURNAL OF CLINICAL ONCOLOGY*
Genovese, J. M., Berek, J. S.
2016; 34 (15): 1820-+
- **Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation** *JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY*
Lum, D. A., Sokol, E. R., Berek, J. S., Schulkin, J., Chen, L., McElwain, C., Wright, J. D.
2016; 23 (4): 548-556
- **In Reply.** *Obstetrics and gynecology*
Parker, W. H., Kaunitz, A. M., Pritts, E. A., Olive, D. L., Chalas, E., Clarke-Pearson, D. L., Berek, J. S.
2016; 127 (5): 966-967
- **An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas** *JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY*
Parker, W., Berek, J. S., Pritts, E., Olive, D., Kaunitz, A. M., Chalas, E., Clarke-Pearson, D., Goff, B., Bristow, R., Taylor, H. S., Farias-Eisner, R., Fader, A., Maxwell, et al
2016; 23 (3): 303-8
- **U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women?** *Obstetrics and gynecology*
Parker, W. H., Kaunitz, A. M., Pritts, E. A., Olive, D. L., Chalas, E., Clarke-Pearson, D. L., Berek, J. S.
2016; 127 (1): 18-22
- **US Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas** *OBSTETRICS AND GYNECOLOGY*
Parker, W. H., Kaunitz, A. M., Pritts, E. A., Olive, D. L., Chalas, E., Clarke-Pearson, D. L., Berek, J. S.
2016; 127 (1): 18-22
- **Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial.** *Journal for immunotherapy of cancer*
Gray, H. J., Benigno, B., Berek, J., Chang, J., Mason, J., Mileskin, L., Mitchell, P., Moradi, M., Recio, F. O., Michener, C. M., Secord, A. A., Tchabo, N. E., Chan, et al
2016; 4: 34-?
- **Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer** *NATURE REVIEWS CANCER*
Bowtell, D. D., Boehm, S., Ahmed, A. A., Aspuria, P., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., Brenton, J. D., Chiappinelli, K. B., Martins, et al
2015; 15 (11): 668-679
- **IS IT TIME TO CHANGE THE PRIMARY ENDPOINT IN CLINICAL TRIALS IN RECURRENT OVARIAN CANCER (ROC)? SYMPTOM BURDEN AND OUTCOMES IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE ROC RECEIVING >= 3 LINES OF CHEMOTHERAPY (PPS) - THE GYNECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)**
Friedlander, M., Stockler, M., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P., Oza, A., Avall-Lundqvist, E., Berek, et al
WILEY-BLACKWELL.2015: 111
- **BASELINE PREDICTORS OF EARLY TREATMENT FAILURE IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC) RECEIVING >= 3 LINES OF CHEMOTHERAPY- THE GYNAECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)**
Roncolato, F., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P., Oza, A., Avall-Lundqvist, E., Berek, J., Sjoquist, et al
WILEY-BLACKWELL.2015: 125
- **Impact of the 2014 FDA Warnings Against Laparoscopic Power Morcellation.** *Journal of minimally invasive gynecology*

- Lum, D., Berek, J. S., Sheikhi, F., Sokol, E. R.
2015; 22 (6S): S77-?
- **Cancer of the ovary, fallopian tube, and peritoneum** *INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS*
Berek, J. S., Crum, C., Friedlander, M.
2015; 131: S111-S122
 - **Validation of the measure of ovarian symptoms and treatment concerns (MOST), a patient-reported outcome measure (PROM) of symptom burden and subjective benefit with chemotherapy in recurrent ovarian cancer (ROC)**
King, M., Stockler, M., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P., Oza, A., Avall-Lundqvist, E., Berek, et al
SPRINGER.2015: 22-23
 - **The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis** *GYNECOLOGICAL SURGERY*
Pritts, E. A., Vanness, D. J., Berek, J. S., Parker, W., Feinberg, R., Feinberg, J., Olive, D. L.
2015; 12 (3): 165-77
 - **ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.**
Mirza, M., Mortensen, C., Avall-Lundqvist, E., Bjorge, L., Berek, J. S., Herrstedt, J., Holm, A., Kirkegaard, T., Maenpaa, J.
AMER SOC CLINICAL ONCOLOGY.2015
 - **Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/ refractory (PRR) and potentially platinum sensitive ROC receiving >= 3 lines of chemotherapy (PPS >= 3)-The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).**
Friedlander, M., Stockler, M. R., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P. P., Oza, A. M., Avall-Lundqvist, E., Berek, et al
AMER SOC CLINICAL ONCOLOGY.2015
 - **Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS >= 3) recurrent ovarian cancer (ROC) receiving >= 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).**
Roncolato, F. T., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P. P., Oza, A. M., Avall-Lundqvist, E., Berek, J. S., Sjoquist, et al
AMER SOC CLINICAL ONCOLOGY.2015
 - **Immunotherapeutic approaches to ovarian cancer treatment.** *Journal for immunotherapy of cancer*
Chester, C., Dorigo, O., Berek, J. S., Kohrt, H.
2015; 3: 7-?
 - **The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis.** *Gynecological surgery*
Pritts, E. A., Vanness, D. J., Berek, J. S., Parker, W., Feinberg, R., Feinberg, J., Olive, D. L.
2015; 12 (3): 165-177
 - **Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer** *AMERICAN JOURNAL OF SURGICAL PATHOLOGY*
Mills, A. M., Liou, S., Ford, J. M., Berek, J. S., Pai, R. K., Longacre, T. A.
2014; 38 (11): 1501-1509
 - **Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer A Phase II Study** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
Berek, J. S., Edwards, R. P., Parker, L. P., DeMars, L. R., Herzog, T. J., Lentz, S. S., Morris, R. T., Akerley, W. L., Holloway, R. W., Method, M. W., Plaxe, S. C., Walker, J. L., Friccius-Quecke, et al
2014; 24 (9): 1583-1589
 - **Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53.** *International journal of oncology*
Park, S., Lee, J. H., Berek, J. S., Hu, M. C.
2014; 45 (4): 1691-1698
 - **A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial).**

Matulonis, U., Mahner, S., Wenham, R., Ledermann, J. A., Monk, B. J., Campo, J., Berek, J. S., Vergote, I., Fabbro, M., Katsaros, D., Marth, C., Lorusso, D., Herrstadt, et al
AMER SOC CLINICAL ONCOLOGY.2014

- **Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation.** *Scientific reports*
Hu, T., Chung, Y. M., Guan, M., Ma, M., Ma, J., Berek, J. S., Hu, M. C.
2014; 4: 5810-?
- **Multidisciplinary Approach to Diagnosis and Treatment of Early Cancer** *GYNECOLOGIC CANCERS: A MULTIDISCIPLINARY APPROACH TO DIAGNOSIS AND MANAGEMENT*
Fuh, K. C., Berek, J. S., Odunsi, K., Pejovic, T.
2014: 179–84
- **FOXO3 tumor suppressor and out-FOXing cancer: Pathways to drug discovery**
Hu, T., Chung, Y., Park, S., Ma, J., Berek, J. S., Hu, M.
SPANDIDOS PUBL LTD.2014: S120
- **A statement on abortion by 100A professors of obstetrics: 40 years later** *CONTRACEPTION*
Archer, D. F., Autry, A. (., Barbieri, R. L., Berek, J. S., Berga, S. L., Bernstein, I. M., Brodman, M., Brown, H., Buekens, P., Bulun, S. E., Burkman, R. T., Campbell, W. A., Carson, et al
2013; 88 (4): 568-576
- **Chemoimmunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer: A Phase I Dose-Escalation Study** *CANCER IMMUNOLOGY RESEARCH*
Simpkins, F., Flores, A., Chu, C., Berek, J. S., Lucci, J., Murray, S., Bauman, J., Struemper, H., Germaschewski, F., Jonak, Z., Gardner, O., Toso, J., Coukos, et al
2013; 1 (3): 168-178
- **A statement on abortion by 100 professors of obstetrics: 40 years later** *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY*
Archer, D. F., Autry, A., Barbieri, R. L., Berek, J. S., Berga, S. L., Bernstein, I. M., Brodman, M., Brown, H., Buekens, P., Bulun, S. E., Burkman, R. T., Campbell, W. A., Carson, et al
2013; 209 (3): 193–99
- **In reply.** *Obstetrics and gynecology*
Parker, W. H., Feskanich, D., Broder, M. S., Chang, E., Shoupe, D., Farquhar, C. M., Berek, J. S., Manson, J. E.
2013; 122 (2): 396-?
- **Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study** *EDITORIAL COMMENT OBSTETRICAL & GYNECOLOGICAL SURVEY*
Parker, W. H., Feskanich, D., Broder, M. S., Chang, E., Shoupe, D., Farquhar, C. M., Berek, J. S., Manson, J. E.
2013; 68 (8): 561–63
- **Centralized independent disease status adjudication for maintenance treatment evaluation in advanced ovarian cancer setting: A critical analysis of the MIMOSA trial experience.**
Scartoni, S., Pfisterer, J., Sabbatini, P., Berek, J. S., Bertolotti, M., Contini, M., Cristina, G., Otranto, I., Melani, L., Poggiali, G., Maggi, C., Capriati, A., Simonelli, et al
AMER SOC CLINICAL ONCOLOGY.2013
- **Effect of metformin on recurrence-free survival and overall survival in diabetic patients affected by advanced ovarian cancer**
Simonelli, C., Bertolotti, M., Sabbatini, P., Berek, J. S., Pfisterer, J., Binaschi, M., Otranto, I., Maggi, C., Scartoni, S., Capriati, A.
AMER SOC CLINICAL ONCOLOGY.2013
- **Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study** *47th Annual Meeting of American-Society-of-Clinical-Oncology (ASCO)*
Sabbatini, P., Harter, P., Scambia, G., Sehouli, J., Meier, W., Wimberger, P., Baumann, K. H., Kurzeder, C., Schmalfeldt, B., Cibula, D., Bidzinski, M., Casado, A., Martoni, et al
AMER SOC CLINICAL ONCOLOGY.2013: 1554–61
- **Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study** *OBSTETRICS AND GYNECOLOGY*
Parker, W. H., Feskanich, D., Broder, M. S., Chang, E., Shoupe, D., Farquhar, C. M., Berek, J. S., Manson, J. E.

2013; 121 (4): 709-716

- **Cancer of the ovary, fallopian tube, and peritoneum** *INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS*
Berek, J. S., Crum, C., Friedlander, M.
2012; 119: S118-S129
- **FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage** *NATURE COMMUNICATIONS*
Chung, Y. M., Park, S., Tsai, W., Wang, S., Ikeda, M., Berek, J. S., Chen, D. J., Hu, M. C.
2012; 3
- **A study of autologous dendritic cell therapy targeting mucin-1 for treatment of patients with epithelial ovarian cancer in first remission.**
Berek, J. S., Goh, J. C., Gray, H. J., Florica, J., Mason, J. R.
AMER SOC CLINICAL ONCOLOGY.2012
- **A phase I, dose escalation trial to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) in combination with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer**
Simpkins, F., Flores, A. M., Chu, C., Lucci, J. A., Berek, J. S., Coukos, G., Bauman, J. W., Murray, S., Struemper, H., Germaschewski, F., Jonak, Z., Gardner, O. S., Toso, et al
AMER SOC CLINICAL ONCOLOGY.2012
- **Current Management of Vulvar Cancer** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Fuh, K. C., Berek, J. S.
2012; 26 (1): 45-?
- **A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection** *ANNALS OF SURGICAL ONCOLOGY*
Tian, W., Chi, D. S., Sehouli, J., Trope, C. G., Jiang, R., Ayhan, A., Cormio, G., Xing, Y., Breitbach, G., Braicu, E. I., Rabbitt, C. A., Oksefjell, H., Fotopoulou, et al
2012; 19 (2): 597-604
- **Rethinking ovarian cancer: recommendations for improving outcomes** *NATURE REVIEWS CANCER*
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., Friedlander, M., Gabra, H., Kaye, et al
2011; 11 (10): 719-725
- **Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort** *BRITISH JOURNAL OF CANCER*
Zang, R. Y., Harter, P., Chi, D. S., Sehouli, J., Jiang, R., Trope, C. G., Ayhan, A., Cormio, G., Xing, Y., Wollschlaeger, K. M., Braicu, E. I., Rabbitt, C. A., Oksefjell, et al
2011; 105 (7): 890-896
- **Personalizing CA125 Levels for Ovarian Cancer Screening** *CANCER PREVENTION RESEARCH*
Dorigo, O., Berek, J. S.
2011; 4 (9): 1356-1359
- **First-Line Therapy in Ovarian Cancer Trials** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
Thigpen, T., duBois, A., McAlpine, J., DiSaia, P., Fujiwara, K., Hoskins, W., Kristensen, G., Mannel, R., Markman, M., Pfisterer, J., Quinn, M., Reed, N., Swart, et al
2011; 21 (4): 756-762
- **SYK promotes tumor progression in ovarian cancer cell lines**
Sultan, A., Wang, C. Y., Duran, G. E., Francisco, E., Berek, J. S., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2011
- **Abagovomab for ovarian cancer** *EXPERT OPINION ON BIOLOGICAL THERAPY*
Pfisterer, J., Harter, P., Simonelli, C., Peters, M., Berek, J., Sabbatini, P., du Bois, A.
2011; 11 (3): 395-403
- **Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer** *IMMUNOTHERAPY*
Grisham, R. N., Berek, J., Pfisterer, J., Sabbatini, P.
2011; 3 (2): 153-162

- **Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy: Recommendations Based on Risk of Ovarian Cancer Reply** *OBSTETRICS AND GYNECOLOGY*
Berek, J. S.
2011; 117 (2): 404
- **Strategies and Goals: The Future of the International Gynecologic Cancer Society IGCS Presidential Address** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
Berek, J. S.
2010; 20 (9): 1434-1439
- **Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy Recommendations Based on Risk of Ovarian Cancer** *OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Chalas, E., Edelson, M., Moore, D. H., Burke, W. M., Cliby, W. A., Berchuck, A.
2010; 116 (3): 733-743
- **Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy** *76th Annual Meeting of the Pacific-Coast-Obstetrical-and-Gynecological-Society*
Nicodemus, C. F., Wang, L., Lucas, J., Varghese, B., Berek, J. S.
MOSBY-ELSEVIER.2010
- **TLR3 agonists as immunotherapeutic agents** *IMMUNOTHERAPY*
Nicodemus, C. F., Berek, J. S.
2010; 2 (2): 137-40
- **The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade** *GYNECOLOGIC ONCOLOGY*
Kandalaf, L. E., Singh, N., Liao, J. B., Facciabene, A., Berek, J. S., Powell, D. J., Coukos, G.
2010; 116 (2): 222-233
- **Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study** *GYNECOLOGIC ONCOLOGY*
Fleming, G. F., Sill, M. W., Darcy, K. M., McMeekin, D. S., Thigpen, J. T., Adler, L. M., Berek, J. S., Chapman, J. A., Disilvestro, P. A., Horowitz, I. R., Fiorica, J. V.
2010; 116 (1): 15-20
- **Long-Term Implications of Oophorectomy at the Time of Hysterectomy for Benign Disease** *AMENORRHEA: A CASE-BASED, CLINICAL GUIDE*
Shoupe, D., Berek, J. S., Santoro, N. F., NealPerry, G.
2010: 187-201
- **Lymph Node-Positive Stage IIIC Ovarian Cancer A Separate Entity?** *International Symposium on Advanced Ovarian Cancer - Optimal Therapy*
Berek, J. S.
LIPPINCOTT WILLIAMS & WILKINS.2009: S18-S20
- **Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses' Health Study** *OBSTETRICS AND GYNECOLOGY*
Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., Shoupe, D., Berek, J. S., Hankinson, S., Manson, J. E.
2009; 113 (5): 1027-1037
- **Ovarian Conservation and Long-Term Health Outcomes in the Nurses' Health Study**
Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., Shoupe, D., Berek, J. S., Hankinson, S., Manson, J. E.
LIPPINCOTT WILLIAMS & WILKINS.2009: E365
- **Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer The Gynecologic Oncology Group Experience** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
Markman, M., Brady, M., Hutson, A., Berek, J. S.
2009; 19 (2): 223-229
- **Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Berek, J., Taylor, P., McGuire, W., Smith, L. M., Schultes, B., Nicodemus, C. F.

2009; 27 (3): 418-425

- **HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review** *GYNECOLOGIC ONCOLOGY*
Karam, A., Berek, J. S., Stenson, A., Rao, J., Dorigo, O.
2008; 111 (3): 568-571
- **Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007** *GYNECOLOGIC ONCOLOGY*
Ashworth, A., Balkwill, F., Bast, R. C., Berek, J. S., Kaye, A., Boyd, J. A., Mills, G., Weinstein, J. N., Woolley, K., Workman, P.
2008; 108 (3): 652-657
- **Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer** *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY*
Chan, J. K., Kapp, D. S., Cheung, M. K., Shin, J. Y., Stieglitz, D., Husain, A., Teng, N. N., Berek, J. S., Osann, K., Guo, H.
2008; 198 (2)
- **Her2neu over-expression and PI3kinase/Akt pathway activation in Paget's disease of the vulva. 55th Annual Meeting of the Society-for-Gynecologic-Investigation**
Stenson, A., Behjatnia, B., Shamonki, J., Rao, J., Karam, A., Berek, J., Dorigo, O.
SAGE PUBLICATIONS INC.2008: 307A-307A
- **Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths** *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY*
Ueda, S. M., Kapp, D. S., Cheung, M. K., Shin, J. Y., Osann, K., Husain, A., Teng, N. N., Berek, J. S., Chan, J. K.
2008; 198 (2)
- **CA125 velocity at relapse is a highly significant predictor of survival post relapse: Results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer** *JOURNAL OF IMMUNOTHERAPY*
Berek, J. S., Taylor, P. T., Nicodemus, C. F.
2008; 31 (2): 207-214
- **NEZHAT'S OPERATIVE GYNECOLOGIC LAPAROSCOPY AND HYSTEROSCOPY Forewords** *NEZHAT'S OPERATIVE GYNECOLOGIC LAPAROSCOPY AND HYSTEROSCOPY, 3RD EDITION*
Krummel, T. M., Giudice, L. C., Cohen, C. J., Berek, J. S., Nezhat, C., Nezhat, F., Nezhat, C.
2008: XIII-XV
- **Elective oophorectomy in the gynecological patient: when is it desirable?** *CURRENT OPINION IN OBSTETRICS & GYNECOLOGY*
Parker, W. H., Shoupe, D., Broder, M. S., Liu, Z., Farquhar, C., Berek, J. S.
2007; 19 (4): 350-354
- **Vulvar melanoma - A multivariable analysis of 644 patients** *OBSTETRICS AND GYNECOLOGY*
Sugiyama, V. E., Chan, J. K., Shin, J. Y., Berek, J. S., Osann, K., Kapp, D. S.
2007; 110 (2): 296-301
- **Impact of the human papilloma vaccine on cervical cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Chan, J. K., Berek, J. S.
2007; 25 (20): 2975-2982
- **The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13,918 patients** *BRITISH JOURNAL OF CANCER*
Chan, J. K., Urban, R., Hu, J. M., Shin, J. Y., Husain, A., Teng, N. N., Berek, J. S., Osann, K., Kapp, D. S.
2007; 96 (12): 1817-1822
- **Lymphadenectomy in endometrioid uterine cancer staging - How many lymph nodes are enough? A study of 11,443 patients** *CANCER*
Chan, J. K., Urban, R., Cheung, M. K., Shin, J. Y., Husain, A., Teng, N. N., Berek, J. S., Walker, J. L., Kapp, D. S., Osann, K.
2007; 109 (12): 2454-2460
- **Influence of the gynecologic oncologist on the survival of ovarian cancer patients** *OBSTETRICS AND GYNECOLOGY*
Chan, J. K., Kapp, D. S., Shin, J. Y., Husain, A., Teng, N. N., Berek, J. S., Osann, K., Leiserowitz, G. S., Cress, R. D., O'Malley, C.
2007; 109 (6): 1342-1350

- **Ovarian conservation at the time of hysterectomy for benign disease** *CLINICAL OBSTETRICS AND GYNECOLOGY*
Parker, W. H., Broder, M. S., Liu, Z., Shoupe, D., Farquhar, C., Berek, J. S.
2007; 50 (2): 354-361
- **Elective oophorectomy for benign gynecological disorders** *MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY*
Shoupe, D., Parker, W. H., Broder, M. S., Liu, Z., Farquhar, C., Berek, J. S.
2007; 14 (3): 580-585
- **Association of lymphadenectomy and survival in stage I ovarian cancer patients - In reply** *OBSTETRICS AND GYNECOLOGY*
Chan, J. K., Munro, E., Cheung, M., Husain, A., Teng, N. N., Berek, J. S., Osann, K.
2007; 109 (4): 1000-1001
- **Prognostic factors for uterine cancer in reproductive-aged women** *OBSTETRICS AND GYNECOLOGY*
Lee, N. K., Cheung, M. K., Shin, J. Y., Husain, A., Teng, N. N., Berek, J. S., Kapp, D. S., Sann, K., Chan, J. K.
2007; 109 (3): 655-662
- **A multivariate analysis of vulvar melanomas: A study of 359 patients**
Sugiyama, V. E., Shin, J. Y., Osann, K., Kapp, D. S., Husain, A., Teng, N. N., Berek, J. S., Chan, J. K.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2007: S5-S6
- **Racial disparities in the surgical treatment of epithelial ovarian cancer in the United States**
Chan, J. K., Zhang, M., Hu, J., Shin, J. Y., Husain, A., Teng, N. N., Berek, J. S., Kapp, D. S., Osann, K.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2007: S31-S31
- **Factors responsible for the increase in death rate of women diagnosed with uterine corpus cancer**
Ueda, S. M., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., Berek, J. S., Kapp, D. S., Chan, J. K.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2007: S8-S8
- **Access to gynecologic oncologists and its impact on survival of women with epithelial ovarian cancer**
Chan, J. K., Shin, J. Y., Husain, A., Teng, N. N., Berek, J. S., Kapp, D. S., Osann, K., Leiserowitz, G., O'Malley, C.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2007: S23-S23
- **CA125: Megadaltons of novel opportunities** *GYNECOLOGIC ONCOLOGY*
Dorigo, O., Berek, J. S.
2007; 104 (3): 505-507
- **Prognostic factors responsible for survival in sex cord stromal tumors of the ovary- An analysis of 376 women** *GYNECOLOGIC ONCOLOGY*
Zhang, M., Cheung, M. K., Shin, J. Y., Kapp, D. S., Husain, A., Teng, N. N., Berek, J. S., Osann, K., Chan, J. K.
2007; 104 (2): 396-400
- **Association of lymphadenectomy and survival in stage I ovarian cancer patients** *OBSTETRICS AND GYNECOLOGY*
Chan, J. K., Munro, E. G., Cheung, M. K., Husain, A., Teng, N. N., Berek, J. S., Osann, K.
2007; 109 (1): 12-19
- **The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma** *GYNECOLOGIC ONCOLOGY*
Parthasarathy, A., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., Berek, J. S., Kapp, D. S., Chan, J. K.
2006; 103 (3): 1095-1099
- **Ovarian cancer in younger vs older women: a population-based analysis** *BRITISH JOURNAL OF CANCER*
Chan, J. K., Urban, R., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., Kapp, D. S., Berek, J. S., Leiserowitz, G. S.
2006; 95 (10): 1314-1320
- **Response to commentaries on retention of the ovaries and long-term survival after hysterectomy** *CLIMACTERIC*
Parker, W. H., Broder, M. S., Liu, Z., Shoupe, D., Farquhar, C., Berek, J. S.
2006; 9 (5): 396-398
- **Patterns and progress in ovarian cancer over 14 years** *OBSTETRICS AND GYNECOLOGY*
Chan, J. K., Cheung, M. K., Husain, A., Teng, N. N., West, D., Whittemore, A. S., Berek, J. S., Osann, K.

2006; 108 (3): 521-528

- **Intraperitoneal chemotherapy for ovarian cancer** *CURRENT OPINION IN ONCOLOGY*
Hamilton, C. A., Berek, J. S.
2006; 18 (5): 507-515
- **The number of lymph nodes with metastatic disease portends for a poorer prognosis in women with stage IIIc-IV endometrioid uterine cancer.** *42nd Annual Meeting of the American-Society-of-Clinical-Oncology*
Chan, J. K., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., Berek, J. S., Kapp, D. S.
AMER SOC CLINICAL ONCOLOGY.2006: 265S-265S
- **The role of extensive lymphadenectomy in stage I ovarian cancer.** *42nd Annual Meeting of the American-Society-of-Clinical-Oncology*
Munro, E. G., Lee, N. K., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., Kapp, D. S., Berek, J. S., Chan, J. K.
AMER SOC CLINICAL ONCOLOGY.2006: 272S-272S
- **The impact of lymphadenectomy in women with endometrioid uterine cancer: A study of 39,396 women.** *42nd Annual Meeting of the American-Society-of-Clinical-Oncology*
Lee, N. K., Wu, H., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., Berek, J. S., Kapp, D. S., Chan, J. K.
AMER SOC CLINICAL ONCOLOGY.2006: 256S-256S
- **The role of surgical staging in grade 1 endometrioid corpus cancer.** *42nd Annual Meeting of the American-Society-of-Clinical-Oncology*
Chan, J. K., Guo, H., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., Berek, J. S., Kapp, D. S.
AMER SOC CLINICAL ONCOLOGY.2006: 258S-258S
- **Surgery for ovarian cancer: how to improve survival** *LANCET*
Bristow, R. E., Berek, J. S.
2006; 367 (9522): 1558-1560
- **10th Biennial Helene Harris Memorial Trust Meeting** *CANCER RESEARCH*
Balkwill, F. R., Ashworth, A., Bast, R. C., Berek, J. S., Boyd, J., Disis, M. L., Gabra, H., Gore, M. E., HAMILTON, T. C., Jacobs, I. J., Kaye, S. B., Kohn, E. C., Mills, et al
2006; 66 (6): 2904-2906
- **Progress in ovarian cancer research: Proceedings of the 5th biennial ovarian cancer research symposium** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
Disis, M. L., Rivkin, S. E., Baron, A., Markman, M., Connolly, D., Ueland, F., Kohn, E., Trimble, E., Berek, J. S.
2006; 16 (2): 463-469
- **An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
Bryan, D. N., Radbod, R., Berek, J. S.
2006; 16 (1): 125-134
- **Pelvic exenteration for recurrent gynecologic malignancy: Survival and morbidity analysis of the 45-year experience at UCLA** *GYNECOLOGIC ONCOLOGY*
Berek, J. S., Howe, C., Lagasse, L. D., Hacker, N. F.
2005; 99 (1): 153-159
- **Design, conduct and evaluation of a communication course for oncology fellows** *JOURNAL OF CANCER EDUCATION*
Lenzi, R., Baile, W. F., Berek, J., Back, A., Buckman, R., Cohen, L., Parker, P. A.
2005; 20 (3): 143-149
- **Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignancies** *GYNECOLOGIC ONCOLOGY*
Elkas, J. C., Berek, J. S., Leuchter, R., Lagasse, L. D., Karlan, B. Y.
2005; 97 (2): 685-692
- **Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial** *GYNECOLOGIC ONCOLOGY*
Monk, B. J., Wang, J. M., Im, S., Stock, R. J., Peters, W. A., Liu, P. Y., Barrett, R. J., Berek, J. S., Souhami, L., Grigsby, P. W., Gordon, W., ALBERTS, D. S.
2005; 96 (3): 721-728

- **Monoclonal antibody therapy of ovarian cancer** *EXPERT REVIEW OF ANTICANCER THERAPY*
Nicodemus, C. F., Berek, J. S.
2005; 5 (1): 87-96
- **Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study** *GYNECOLOGIC ONCOLOGY*
Muggia, F. M., Blessing, J. A., Waggoner, S., Berek, J. S., Monk, B. J., Sorosky, J., Pearl, M. L.
2005; 96 (1): 108-111
- **Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer** *39th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Berek, J. S., Taylor, P. T., Gordon, A., Cunningham, M. J., Finkler, N., Orr, J., Rivkin, S., Schultes, B. C., Whiteside, T. L., Nicodemus, C. F.
AMER SOC CLINICAL ONCOLOGY.2004: 3507-16
- **Using fresh tissue dissection to teach human anatomy in the clinical years** *ACADEMIC MEDICINE*
Robinson, A. G., Metten, S., Guiton, G., Berek, J.
2004; 79 (7): 711-716
- **Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab** *EXPERT OPINION ON BIOLOGICAL THERAPY*
Berek, J. S.
2004; 4 (7): 1159-1165
- **Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy** *CLINICAL CANCER RESEARCH*
Nouriani, M., Bahador, A., Berek, J. S., Cheng, J. P., Chi, D. S., Cliby, W. A., Del Priore, G., Dodson, M. K., Duggan, B. D., Gershenson, D. M., Lentz, S. E., Penson, R. T., Robinson, et al
2004; 10 (8): 2681-2686
- **Lymphovascular and perineural invasion in the parametria: A prognostic factor for early-stage cervical cancer** *OBSTETRICS AND GYNECOLOGY*
Memarzadeh, S., Natarajan, S., Dandade, D. P., Ostrzega, N., Saber, P. A., Busuttil, A., Lentz, S. E., Berek, J. S.
2003; 102 (3): 612-619
- **Current research and treatment for epithelial ovarian cancer - A Position Paper from the Helene Harris Memorial Trust** *EUROPEAN JOURNAL OF CANCER*
Balkwill, F., Bast, R. C., Berek, J., Chenevix-Trench, G., Gore, M., Hamilton, T., Jacobs, I., Mills, G., Souhami, R., Urban, N., Ursulic, S., Smyth, J.
2003; 39 (13): 1818-1827
- **Cervical cancer: An opportunity to prevent and cure** *CANCER JOURNAL*
Berek, J. S.
2003; 9 (5): 325-326
- **Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies** *GYNECOLOGIC ONCOLOGY*
Gold, M. A., Walker, J. L., Berek, J. S., Hallum, A. V., Garcia, D. J., ALBERTS, D. S.
2003; 90 (2): 325-330
- **Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study** *GYNECOLOGIC ONCOLOGY*
Fracasso, P. M., Blessing, J. A., Wolf, J., Rocereto, T. F., Berek, J. S., Waggoner, S.
2003; 90 (1): 177-180
- **Progress in the management of gynecologic cancer: consensus summary statement.** *Journal of clinical oncology*
Cannistra, S. A., Bast, R. C., Berek, J. S., Bookman, M. A., Crum, C. P., DePriest, P. D., Garber, J. E., Koh, W., Markman, M., McGuire, W. P., Rose, P. G., Rowinsky, E. K., Rustin, et al
2003; 21 (10): 129s-132s
- **Biologic and immunologic therapies for ovarian cancer.** *Journal of clinical oncology*
Berek, J. S., Schultes, B. C., Nicodemus, C. F.
2003; 21 (10): 168s-174s
- **Surgical resection of solitary brain metastasis from cervical cancer** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*

- Tajran, D., Berek, J. S.
2003; 13 (3): 368-370
- **The use of continuous infusion topotecan in persistent and recurrent ovarian cancer** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
Elkas, J. C., Holschneider, C. H., Katz, B., Li, A. J., Louie, R., McGonigle, K. F., Berek, J. S.
2003; 13 (2): 138-141
 - **CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
Memarzadeh, S., Lee, S. B., Berek, J. S., Farias-Eisner, R.
2003; 13 (2): 120-124
 - **Simplification of the new Bethesda 2001 classification System** *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY*
Berek, J. S.
2003; 188 (3): S2-S5
 - **Specific keynote: Immunological therapy for ovarian cancer** *8th International Forum on Ovarian Cancer*
Berek, J. S., Dorigo, O., Schultes, B., Nicodemus, C.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2003: S105-S109
 - **FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
Memarzadeh, S., Holschneider, C. H., Bristow, R. E., JONES, N. L., Fu, Y. S., Karlan, B. Y., Berek, J. S., Farias-Eisner, R.
2002; 12 (5): 454-458
 - **Advances in the management of epithelial ovarian cancer** *JOURNAL OF REPRODUCTIVE MEDICINE*
Memarzadeh, S., Berek, J. S.
2001; 46 (7): 621-629
 - **A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature** *JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS*
Ghosh, K., Dorigo, O., Bristow, R., Berek, J.
2000; 191 (2): 212-215
 - **Interferon plus chemotherapy for primary treatment of ovarian cancer** *LANCET*
Berek, J. S.
2000; 356 (9223): 6-7
 - **[Epithelial ovarian cancer (advanced stage): consensus conference (1998)].** *Gynecologie, obstetrique & fertilité*
Berek, J. S., Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J., Eisenhauer, E. A., Gore, M., Grenman, S., HAMILTON, T. C., Hansen, S. W., Harper, P. G., Horvath, G., Kaye, et al
2000; 28 (7-8): 576-583
 - **Ovarian cancer: Epidemiology, biology, and prognostic factors** *SEMINARS IN SURGICAL ONCOLOGY*
Holschneider, C. H., Berek, J. S.
2000; 19 (1): 3-10
 - **Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125** *GYNECOLOGIC ONCOLOGY*
Berek, J. S.
2000; 77 (2): 225-226
 - **Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix** *JOURNAL OF CLINICAL ONCOLOGY*
Peters, W. A., Liu, P. Y., Barrett, R. J., Stock, R. J., Monk, B. J., Berek, J. S., Souhami, L., Grigsby, P., Gordon, W., ALBERTS, D. S.
2000; 18 (8): 1606-1613
 - **Fraud. What is the evidence?** *Care management journals : Journal of case management ; The journal of long term home health care*
Berek, J., Gutierrez, N., Stone, J., Testa, L.
2000; 2 (1): 44-53

- **IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile** *JOURNAL OF IMMUNOLOGY*
Horton, H. M., Dorigo, O., Hernandez, P., Anderson, D., Berek, J. S., Parker, S. E.
1999; 163 (12): 6378-6385
- **Endometrial cancer: Recent developments in evaluation and treatment** *ONCOLOGY-NEW YORK*
Chen, L. M., McGonigle, K. F., Berek, J. S.
1999; 13 (12): 1665-?
- **Recurrent mature cystic teratoma presenting as a perihepatic mass** *OBSTETRICS AND GYNECOLOGY*
Chen, L. M., Nelson, S. D., Berek, J. S.
1999; 94 (5): 856-856
- **Intraperitoneal interferon-alpha in residual ovarian carcinoma: A Phase II Gynecologic Oncology Group study** *GYNECOLOGIC ONCOLOGY*
Berek, J. S., Markman, M., Stonebraker, B., Lentz, S. S., Adelson, M. D., DeGeest, K., Moore, D.
1999; 75 (1): 10-14
- **Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study** *GYNECOLOGIC ONCOLOGY*
Berek, J. S., Markman, M., Blessing, J. A., Kucera, P. R., Nelson, B. E., Anderson, B., Hanjani, P.
1999; 74 (1): 48-52
- **Advanced epithelial ovarian cancer: 1998 consensus statements** *Workshop on Advanced Ovarian Cancer - What Do We Know and What Do We Need*
Berek, J. S., Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J., Eisenhauer, E. A., Gore, M., Grenman, S., HAMILTON, T. C., Hansen, S. W., Harper, P. G., Horvath, G., Kaye, et al
OXFORD UNIV PRESS.1999: 87-92
- **Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future?** *Workshop on Advanced Ovarian Cancer - What Do We Know and What Do We Need*
HAMILTON, T. C., Berek, J. S., Kaye, S. B.
OXFORD UNIV PRESS.1999: 69-73
- **Surgery during chemotherapy and at relapse of ovarian cancer** *Workshop on Advanced Ovarian Cancer - What Do We Know and What Do We Need*
Berek, J. S., Trope, C., Vergote, I.
OXFORD UNIV PRESS.1999: 3-7
- **A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma. A gynecologic oncology group study** *GYNECOLOGIC ONCOLOGY*
Feun, L. G., Blessing, J. A., Major, F. J., Disaia, P. J., Alvarez, R. D., Berek, J. S.
1998; 71 (3): 410-415
- **Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model** *GYNECOLOGIC ONCOLOGY*
Dorigo, O., Shawler, D. L., Royston, I., SOBOL, R. E., Berek, J. S., Fakhrai, H.
1998; 71 (2): 204-210
- **Psammocarcinoma with an aggressive course** *OBSTETRICS AND GYNECOLOGY*
Poggi, S. H., Bristow, R. E., Nieberg, R. K., Berek, J. S.
1998; 92 (4): 659-661
- **Reducing loss-to-follow-up among women with abnormal Pap smears - Results from a randomized trial testing an intensive follow-up protocol and economic incentives** *MEDICAL CARE*
Marcus, A. C., Kaplan, C. P., Crane, L. A., Berek, J. S., Bernstein, G., Gunning, J. E., McClatchey, M. W.
1998; 36 (3): 397-410
- **Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancer.** *Cancer treatment and research*
Kim, Y. B., Ghosh, K., Ainbinder, S., Berek, J. S.
1998; 95: 253-276

- **Chemotherapy for ovarian cancer** *XV FIGO World Congress of Gynaecology and Obstetrics*
Berek, J. S., Markman, M., McGuire, W. P., Thigpen, J. T., OZOLS, R. F.
PARTHENON PUBLISHING GROUP LTD.1998: 211-218
- **Progress in ovarian cancer** *CURRENT OPINION IN OBSTETRICS & GYNECOLOGY*
Chen, L., Berek, J. S.
1998; 10 (1): 51-56
- **Conclusions and recommendations from the Helene Harris Memorial Trust Sixth Biennial International Forum on Ovarian Cancer, May 10-14, 1997, Los Angeles, California, USA** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
Sharp, F., Blackett, A. D., Berek, J. S., Bast, R. C.
1997; 7 (5): 416-424
- **Gene therapy for ovarian cancer: Development of novel treatment strategies** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
Dorigo, O., Berek, J. S.
1997; 7 (1): 1-13
- **Dysgerminoma: The role of conservative surgery** *GYNECOLOGIC ONCOLOGY*
Casey, A. C., Bhodauria, S., Shapter, A., NIEBERG, R., Berek, J. S., FARIASEISNER, R.
1996; 63 (3): 352-357
- **Complete debulking of epithelial ovarian cancer.** *cancer journal from Scientific American*
Berek, J. S.
1996; 2 (3): 132-133
- **Mixed mesodermal sarcoma of the ovary in a young patient** *EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY*
Fowler, J. M., Nathan, L., Nieberg, R. K., Berek, J. S.
1996; 65 (2): 249-253
- **Evidence for a unifocal origin in familial ovarian cancer** *14th Annual Meeting of the American-Gynecological-and-Obstetrical-Society*
Gallion, H. H., Guarino, D., DePriest, P. D., VANNAGELL, J. R., Vaccarello, L., Berek, J. S., Pieretti, M.
MOSBY-ELSEVIER.1996: 1102-6
- **Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma** *GYNECOLOGIC ONCOLOGY*
Kim, Y. B., Berek, J. S., MARTINEZMAZA, O., Satyaswaroop, P. G.
1996; 61 (1): 97-100
- **Complications of pelvic radiation therapy for gynecologic malignancies in elderly women** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
McGonigle, K. F., Lavey, R. S., Juillard, G., Berek, J. S.
1996; 6 (2): 149-155
- **OVARIAN-CANCER SCREENING - THE USE OF SERIAL COMPLEMENTARY TUMOR-MARKERS TO IMPROVE SENSITIVITY AND SPECIFICITY FOR EARLY DETECTION** *5th National Conference of the American-Cancer-Society on Gynecologic Cancers*
Berek, J. S., Bast, R. C.
WILEY-LISS.1995: 2092-96
- **Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum on Ovarian Cancer, May 4-7, 1995, Glasgow, UK.** *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*
Sharp, F., Blackett, A. D., Leake, R. E., Berek, J. S.
1995; 5 (6): 449-458
- **CONCLUSIONS AND RECOMMENDATIONS FROM THE HELENE-HARRIS-MEMORIAL-TRUST 5TH BIENNIAL INTERNATIONAL FORUM ON OVARIAN-CANCER, MAY 4-7, 1995, GLASGOW, UK** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
Sharp, F., Blackett, A. D., Leake, R. E., Berek, J. S.
1995; 5 (6): 449-458
- **RADIATION-THERAPY FOR ADENOCARCINOMA OF THE UTERINE CERVIX - DOES THE HISTOLOGY MATTER** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*

- Berek, J. S.
1995; 32 (5): 1543-1544
- **OVARIAN-CANCER SPREAD - IS LAPAROSCOPY TO BLAME** *LANCET*
Berek, J. S.
1995; 346 (8969): 200-200
 - **ASSESSMENT OF DOSE-INTENSIVE THERAPY IN SUBOPTIMALLY DEBULKED OVARIAN-CANCER - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY** *JOURNAL OF CLINICAL ONCOLOGY*
McGuire, W. P., Hoskins, W. J., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M. L., Ball, H., Berek, J. S., Woodward, J.
1995; 13 (7): 1589-1599
 - **INTERVAL DEBULKING OF OVARIAN-CANCER - AN INTERIM MEASURE** *NEW ENGLAND JOURNAL OF MEDICINE*
Berek, J. S.
1995; 332 (10): 675-677
 - **INTRAPERITONEAL ADMINISTRATION OF CISPLATIN AND 5-FLUOROURACIL IN RESIDUAL OVARIAN-CANCER - A PHASE-II GYNECOLOGIC-ONCOLOGY-GROUP TRIAL** *GYNECOLOGIC ONCOLOGY*
Braly, P. S., Berek, J. S., Blessing, J. A., Homesley, H. D., Averette, H.
1995; 56 (2): 164-168
 - **A MULTICENTER STUDY OF LAPAROSCOPIC MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL WOMEN** *JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS*
Parker, W. H., Levine, R. L., Howard, F. M., SANSONE, B., Berek, J. S.
1994; 179 (6): 733-737
 - **PROGNOSTIC IMPORTANCE OF INTRAOPERATIVE RUPTURE OF MALIGNANT OVARIAN EPITHELIAL NEOPLASMS** *OBSTETRICS AND GYNECOLOGY*
Parker, W. H., Berek, J. S.
1994; 84 (5): 897-897
 - **CYTOTOXICITY OF NEW AZA-ALKYL LYSOPHOSPHOLIPIDS AGAINST DRUG-SENSITIVE AND RESISTANT HUMAN OVARIAN TUMOR-CELL LINES - ROLE OF FREE-RADICALS AND POTENTIATION OF CYTOTOXICITY BY TNF-ALPHA AND CDDP** *ONCOLOGY REPORTS*
Hourizadeh, A., Broquet, C., MENCIAHUERTA, J. M., BRAQUET, P., Berek, J., Bonavida, B.
1994; 1 (6): 1253-1259
 - **THE INFLUENCE OF TUMOR GRADE, DISTRIBUTION, AND EXTENT OF CARCINOMATOSIS IN MINIMAL RESIDUAL STAGE-III EPITHELIAL OVARIAN-CANCER AFTER OPTIMAL PRIMARY CYTOREDUCTIVE SURGERY** *GYNECOLOGIC ONCOLOGY*
FARIASEISNER, R., Teng, F., Oliveira, M., Leuchter, R., Karlan, B., Lagasse, L. D., Berek, J. S.
1994; 55 (1): 108-110
 - **Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts in pelvic and inguinal lymph nodes.** *Obstetrics and gynecology*
Casey, A. C., Berek, J. S.
1994; 84 (4): 724-726
 - **Advances in the biology of gynecologic cancer.** *Current opinion in oncology*
Gottlieb, W. H., Berek, J. S.
1994; 6 (5): 513-518
 - **SALVAGE THERAPY FOR RECURRENT AND REFRACTORY OVARIAN-CANCER WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY** *GYNECOLOGIC ONCOLOGY*
Broun, E. R., Belinson, J. L., Berek, J. S., McIntosh, D., Hurd, D., Ball, H., Williams, S.
1994; 54 (2): 142-146
 - **Management of Selected Adnexal Masses in Postmenopausal Women by Operative Laparoscopy-A Multicentered Study** *journal of the American Association of Gynecologic Laparoscopists*
Parker, Levine, Howard, SANSONE, Berek
1994; 1 (4): S27-?
 - **SURGICAL-MANAGEMENT OF OVARIAN-CANCER** *SEMINARS IN SURGICAL ONCOLOGY*

- FARIASEISNER, R., Kim, Y. B., Berek, J. S.
1994; 10 (4): 268-275
- **MOLECULAR AND BIOLOGIC FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER** *JOURNAL OF REPRODUCTIVE MEDICINE*
Berek, J. S., MARTINEZMAZA, T.
1994; 39 (4): 241-248
 - **CYTOKINE-INDUCED MODULATION OF TUMOR-SUPPRESSOR GENE-EXPRESSION IN OVARIAN-CANCER CELLS - UP-REGULATION OF P53 GENE-EXPRESSION AND INDUCTION OF APOPTOSIS BY TUMOR-NECROSIS-FACTOR-ALPHA** *12th Annual Meeting of the American-Gynecological-and-Obstetrical-Society*
Gottlieb, W. H., Watson, J. M., Rezai, A., Johnson, M., MARTINEZMAZA, O., Berek, J. S.
MOSBY-YEAR BOOK INC.1994: 1121-30
 - **CONSERVATIVE AND INDIVIDUALIZED SURGERY FOR EARLY SQUAMOUS CARCINOMA OF THE VULVA - THE TREATMENT OF CHOICE FOR STAGE-I AND II (T1-2N0-1M0) DISEASE** *GYNECOLOGIC ONCOLOGY*
FARIASEISNER, R., Cirisano, F. D., GROUSE, D., Leuchter, R. S., Karlan, B. Y., Lagasse, L. D., Berek, J. S.
1994; 53 (1): 55-58
 - **THE EFFECT OF DIAMETER OF LARGEST RESIDUAL DISEASE ON SURVIVAL AFTER PRIMARY CYTOREDUCTIVE SURGERY IN PATIENTS WITH SUBOPTIMAL RESIDUAL EPITHELIAL OVARIAN-CARCINOMA** *12th Annual Meeting of the American-Gynecological-and-Obstetrical-Society*
Hoskins, W. J., McGuire, W. P., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M., Ball, H., Berek, J. S.
MOSBY-YEAR BOOK INC.1994: 974-80
 - **LAPAROSCOPIC MANAGEMENT OF THE ADNEXAL MASS** *OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA*
Parker, W. H., Berek, J. S.
1994; 21 (1): 79-92
 - **UTERINE SARCOMA IN PATIENTS OPERATED ON FOR PRESUMED LEIOMYOMA AND RAPIDLY GROWING LEIOMYOMA** *OBSTETRICS AND GYNECOLOGY*
Parker, W. H., Fu, Y. S., Berek, J. S.
1994; 83 (3): 414-418
 - **Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal carcinomatosis.** *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*
Fowler, J. M., Nieberg, R. K., Schooler, T. A., Berek, J. S.
1994; 4 (1): 43-51
 - **PERITONEAL ADENOCARCINOMA (SEROUS) OF MULLERIAN TYPE - A SUBGROUP OF WOMEN PRESENTING WITH PERITONEAL CARCINOMATOSIS** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
Fowler, J. M., Nieberg, R. K., SCHOOLER, T. A., Berek, J. S.
1994; 4 (1): 43-51
 - **Fine-needle aspiration cytology in the management of gynecologic oncology patients.** *Cancer treatment and research*
Layfield, L. J., Berek, J. S.
1994; 70: 1-13
 - **CONSTITUTIVE PRODUCTION OF MACROPHAGE-COLONY-STIMULATING FACTOR AND INTERLEUKIN-6 BY HUMAN OVARIAN SURFACE EPITHELIAL-CELLS** *EXPERIMENTAL CELL RESEARCH*
LIDOR, Y. J., Xu, F. J., MARTINEZMAZA, O., Olt, G. J., Marks, J. R., Berchuck, A., Ramakrishnan, S., Berek, J. S., Bast, R. C.
1993; 207 (2): 332-339
 - **PROGNOSTIC FACTORS FOR GROIN NODE METASTASIS IN SQUAMOUS-CELL CARCINOMA OF THE VULVA (A GYNECOLOGIC-ONCOLOGY-GROUP-STUDY)** *GYNECOLOGIC ONCOLOGY*
Homesley, H. D., Bundy, B. N., Sedlis, A., YORDAN, E., Berek, J. S., Jahshan, A., MORTEL, R.
1993; 49 (3): 279-283
 - **IMPACT OF CONTRACEPTION ON GYNECOLOGIC CANCERS** *SYMP ON CONTRACEPTIVE CHOICES FOR WOMEN WITH MEDICAL PROBLEMS*
Herbst, A. L., Berek, J. S.
MOSBY-YEAR BOOK INC.1993: 1980-85

- **GROWTH-INHIBITION OF OVARIAN-CANCER CELLS INDUCED BY ANTISENSE IL-6 OLIGONUCLEOTIDES** *GYNECOLOGIC ONCOLOGY*
Watson, J. M., Berek, J. S., MARTINEZMAZA, O.
1993; 49 (1): 8-15
- **SOLITARY RECURRENT METASTASIS OF EPITHELIAL OVARIAN-CANCER IN THE SPLEEN** *GYNECOLOGIC ONCOLOGY*
FARIASEISNER, R., Braly, P., Berek, J. S.
1993; 48 (3): 338-341
- **PRIMARY LEIOMYOSARCOMA OF THE OVARY IN A PERIMENARCHAL FEMALE** *GYNECOLOGIC ONCOLOGY*
Monk, B. J., NIEBERG, R., Berek, J. S.
1993; 48 (3): 389-393
- **SENSITIVITY OF DRUG-RESISTANT HUMAN OVARIAN TUMOR-CELL LINES TO COMBINED EFFECTS OF TUMOR-NECROSIS-FACTOR (TNF-ALPHA) AND DOXORUBICIN - FAILURE OF THE COMBINATION TO MODULATE THE MDR PHENOTYPE** *GYNECOLOGIC ONCOLOGY*
Safrit, J. T., Berek, J. S., Bonavida, B.
1993; 48 (2): 214-220
- **Current management of invasive squamous carcinoma of the vulva.** *Clinics in geriatric medicine*
Farias-Eisner, R., Berek, J. S.
1993; 9 (1): 131-143
- **MOLECULAR AND BIOLOGICAL FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER** *International Workshop on Advanced Ovarian Cancer: where Do We Stand and Where Do We Go*
Berek, J. S., MARTINEZMAZA, O., Hamilton, T., Trope, C., Kaern, J., Baak, J., Rustin, G. J.
OXFORD UNIV PRESS.1993: 3-16
- **TUMOR-MARKERS** *International Workshop on Advanced Ovarian Cancer: where Do We Stand and Where Do We Go*
Rustin, G. J., VANDERBURG, M. E., Berek, J. S.
OXFORD UNIV PRESS.1993: 71-77
- **ADVANCED EPITHELIAL OVARIAN-CANCER - 1993 CONSENSUS STATEMENTS** *ANNALS OF ONCOLOGY*
Allen, D. G., Baak, J., Belpomme, D., Berek, J. S., Bertelsen, K., Huinink, W. W., VANDERBURG, M. E., Calvert, A. H., Conte, P. E., Dauplat, J., Eisenhauer, E. A., Favalli, G., Hacker, et al
1993; 4: 83-88
- **Advanced ovarian cancer. Tumour markers.** *Annals of oncology*
Rustin, G. J., Van der Burg, M. E., Berek, J. S.
1993; 4: 71-77
- **PRESENCE OF INTERLEUKIN 10 (IL-10) IN THE ASCITES OF PATIENTS WITH OVARIAN AND OTHER INTRAABDOMINAL CANCERS** *CYTOKINE*
Gottlieb, W. H., Abrams, J. S., Watson, J. M., VELU, T. J., Berek, J. S., MARTINEZMAZA, O.
1992; 4 (5): 385-390
- **BIOLOGIC AND IMMUNOLOGICAL THERAPY OF OVARIAN-CANCER** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Bookman, M. A., Berek, J. S.
1992; 6 (4): 941-965
- **INTRAPERITONEAL IMMUNOTHERAPY FOR OVARIAN-CANCER WITH ALPHA-INTERFERON** *EUROPEAN JOURNAL OF CANCER*
Berek, J. S.
1992; 28A (4-5): 719-721
- **CHARACTERISTICS OF PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER UNRESPONSIVE TO CISPLATIN-BASED IP CHEMOTHERAPY - LESSONS LEARNED FROM A GYNECOLOGIC ONCOLOGY GROUP PHASE-II TRIAL OF IP CISPLATIN AND RECOMBINANT ALPHA-INTERFERON** *GYNECOLOGIC ONCOLOGY*
Markman, M., Berek, J. S., Blessing, J. A., McGuire, W. P., Bell, J., Homesley, H. D.
1992; 45 (1): 3-8
- **IMPROVING ADHERENCE TO SCREENING FOLLOW-UP AMONG WOMEN WITH ABNORMAL PAP SMEARS - RESULTS FROM A LARGE CLINIC-BASED TRIAL OF 3 INTERVENTION STRATEGIES** *MEDICAL CARE*
Marcus, A. C., Crane, L. A., Kaplan, C. P., READING, A. E., Savage, E., Gunning, J., Bernstein, G., Berek, J. S.

1992; 30 (3): 216-230

- **STIMULATION OF OVARIAN TUMOR-CELL PROLIFERATION WITH MONOCYTE PRODUCTS INCLUDING INTERLEUKIN-1, INTERLEUKIN-6, AND TUMOR-NECROSIS-FACTOR-ALPHA** *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY*
Wu, S., Rodabaugh, K., MARTINEZMAZA, O., Watson, J. M., Silberstein, D. S., BOYER, C. M., Peters, W. P., Weinberg, J. B., Berek, J. S., Bast, R. C.
1992; 166 (3): 997-1007
- **EARLY-STAGE SQUAMOUS-CELL AND ADENOCARCINOMA OF THE CERVIX** *CURRENT OPINION IN OBSTETRICS & GYNECOLOGY*
McGonigle, K. F., Berek, J. S.
1992; 4 (1): 109-119
- **2ND-LOOK VERSUS 2ND NATURE** *GYNECOLOGIC ONCOLOGY*
Berek, J. S.
1992; 44 (1): 1-2
- **Interleukin 6 and cancer treatment.** *In vivo*
Martínez-Maza, O., Berek, J. S.
1991; 5 (6): 583-588
- **CONCURRENT CISPLATIN AND 5-FLUOROURACIL CHEMOTHERAPY AND RADIATION-THERAPY FOR ADVANCED-STAGE SQUAMOUS CARCINOMA OF THE VULVA** *22ND ANNUAL MEETING OF THE SOC OF GYNECOLOGIC ONCOLOGISTS*
Berek, J. S., HEAPS, J. M., Fu, Y. S., Juillard, G. J., Hacker, N. F.
ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS.1991: 197-201
- **ADNEXAL TORSION - AN UNUSUAL CAUSE OF ABDOMINAL-PAIN IN POSTMENOPAUSAL WOMEN** *AMERICAN SURGEON*
Shih, S., Vetto, J. T., Berek, J. S., HEAPS, J. M., Hiatt, J. R.
1991; 57 (5): 327-329
- **CORRELATION OF ENDOCERVICAL CURETTAGE WITH SUBSEQUENT CONE BIOPSY IN THE INVESTIGATION OF ABNORMAL CERVICAL CYTOLOGY** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
TAKAMI, C. Y., Nieberg, R. K., Berek, J. S.
1991; 1 (3): 97-103
- **ASSESSMENT OF CURRENT INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGING OF VULVAR CARCINOMA RELATIVE TO PROGNOSTIC FACTORS FOR SURVIVAL (A GYNECOLOGIC ONCOLOGY GROUP-STUDY)** *9TH ANNUAL MEETING OF THE AMERICAN GYNECOLOGICAL AND OBSTETRICAL SOC*
Homesley, H. D., Bundy, B. N., Sedlis, A., YORDAN, E., Berek, J. S., Jahshan, A., MORTEL, R.
MOSBY-ELSEVIER.1991: 997-1004
- **SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER** *9TH ANNUAL MEETING OF THE AMERICAN GYNECOLOGICAL AND OBSTETRICAL SOC*
Berek, J. S., Chung, C., Kaldi, K., Watson, J. M., Knox, R. M., MARTINEZMAZA, O.
MOSBY-ELSEVIER.1991: 1038-43
- **A PHASE I-II TRIAL OF INTRAPERITONEAL CISPLATIN AND ALPHA-INTERFERON IN PATIENTS WITH PERSISTENT EPITHELIAL OVARIAN-CANCER** *GYNECOLOGIC ONCOLOGY*
Berek, J. S., WELANDER, C., Schink, J. C., Grossberg, H., Montz, F. J., ZIGELBOIM, J.
1991; 40 (3): 237-243
- **FINE-NEEDLE ASPIRATION CYTOLOGY ACCURACY WITH PALPABLE GYNECOLOGIC NEOPLASMS** *GYNECOLOGIC ONCOLOGY*
Layfield, L. J., HEAPS, J. M., Berek, J. S.
1991; 40 (1): 70-73
- **SURGICAL STAGING OF CERVICAL-CANCER** *CLINICAL OBSTETRICS AND GYNECOLOGY*
HEAPS, J. M., Berek, J. S.
1990; 33 (4): 852-863
- **RESISTANCE OF HUMAN OVARIAN-CANCER CELLS TO TUMOR-NECROSIS-FACTOR AND LYMPHOKINE-ACTIVATED KILLER-CELLS - CORRELATION WITH EXPRESSION OF HER2 NEU ONCOGENES** *CANCER RESEARCH*
Lichtenstein, A., Berenson, J., Gera, J. F., Waldburger, K., MARTINEZMAZA, O., Berek, J. S.

1990; 50 (22): 7364-7370

- **MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL WOMEN BY OPERATIVE LAPAROSCOPY - A PILOT-STUDY** *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY*
Parker, W. H., Berek, J. S.
1990; 163 (5): 1574-1577
- **CONSTITUTIVE PRODUCTION OF INTERLEUKIN-6 BY OVARIAN-CANCER CELL-LINES AND BY PRIMARY OVARIAN TUMOR CULTURES** *CANCER RESEARCH*
Watson, J. M., Sensintaffar, J. L., Berek, J. S., MARTINEZMAZA, O.
1990; 50 (21): 6959-6965
- **INTRAPERITONEAL ADOPTIVE IMMUNOTHERAPY FOR PERITONEAL CANCER** *JOURNAL OF CLINICAL ONCOLOGY*
Berek, J. S.
1990; 8 (10): 1610-1612
- **OVARIAN METASTASES ARE RARE IN STAGE-I ADENOCARCINOMA OF THE CERVIX** *OBSTETRICS AND GYNECOLOGY*
Brown, J. V., Fu, Y. S., Berek, J. S.
1990; 76 (4): 623-623
- **SYNERGY IS DOCUMENTED INVITRO WITH LOW-DOSE RECOMBINANT TUMOR-NECROSIS-FACTOR, CISPLATIN, AND DOXORUBICIN IN OVARIAN-CANCER CELLS** *1990 ANNUAL MEETING OF THE SOC OF GYNECOLOGIC ONCOLOGISTS*
Bonavida, B., Tsuchitani, T., ZIGHELBOIM, J., Berek, J. S.
ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS.1990: 333-39
- **SURGICAL-PATHOLOGICAL VARIABLES PREDICTIVE OF LOCAL RECURRENCE IN SQUAMOUS-CELL CARCINOMA OF THE VULVA** *1990 ANNUAL MEETING OF THE SOC OF GYNECOLOGIC ONCOLOGISTS*
HEAPS, J. M., Fu, Y. S., Montz, F. J., Hacker, N. F., Berek, J. S.
ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS.1990: 309-14
- **PATHOPHYSIOLOGY AND MANAGEMENT OF ENDOMETRIAL HYPERPLASIA AND CARCINOMA** *WESTERN JOURNAL OF MEDICINE*
Fu, Y. S., Gambone, J. C., Do, Berek, J. S.
1990; 153 (1): 50-61
- **MALIGNANT NEOPLASMS ARISING IN ENDOMETRIOSIS** *OBSTETRICS AND GYNECOLOGY*
HEAPS, J. M., Nieberg, R. K., Berek, J. S.
1990; 75 (6): 1023-1028
- **CYTOREDUCTIVE SURGERY FOR ADVANCED OVARIAN-CANCER - CARDIOVASCULAR EVALUATION WITH PULMONARY-ARTERY CATHETERS** *GYNECOLOGIC ONCOLOGY*
EISNER, R. F., Montz, F. J., Berek, J. S.
1990; 37 (3): 311-314
- **PHASE-II STUDY OF N-METHYLFORMAMIDE (N-MF) (NSC 3051) IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY** *INVESTIGATIONAL NEW DRUGS*
McGuire, W. P., Blessing, J. A., Berek, J. S., Munoz, A.
1990; 8 (2): 191-194
- **ADJUVANT THERAPY FOR EARLY-STAGE OVARIAN-CANCER** *NEW ENGLAND JOURNAL OF MEDICINE*
Berek, J. S.
1990; 322 (15): 1076-1078
- **RISK-FACTORS FOR THE DEVELOPMENT OF LYMPH-NODE METASTASIS IN VULVAR SQUAMOUS-CELL CARCINOMA** *GYNECOLOGIC ONCOLOGY*
Binder, S. W., Huang, I., Fu, Y. S., Hacker, N. F., Berek, J. S.
1990; 37 (1): 9-16
- **AUGMENTATION OF CYTOTOXICITY OF LYMPHOKINE ACTIVATED KILLER-CELLS ON OVARIAN TUMOR-CELLS BY VARIOUS BIOLOGICAL RESPONSE MODIFIERS** *ANTICANCER RESEARCH*
Nio, Y., ZIGHELBOIM, J., Berek, J. S., Bonavida, B.
1990; 10 (2A): 441-446

- **PELVIC HEMANGIOPERICYTOMAS - A REPORT OF 5 CASES AND LITERATURE-REVIEW** *GYNECOLOGIC ONCOLOGY*
Munoz, A. K., Berek, J. S., Fu, Y. S., HEINTZ, P. A.
1990; 36 (3): 380-382
- **CYCLOHEXIMIDE-INDUCED MODULATION OF TNF-MEDIATED CYTOTOXICITY IN SENSITIVE AND RESISTANT OVARIAN TUMOR-CELLS** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Nio, Y., ZIGHELBOIM, J., Berek, J., Bonavida, B.
1990; 26 (1): 1-8
- **RESECTION OF DIAPHRAGMATIC PERITONEUM AND MUSCLE - ROLE IN CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER** *GYNECOLOGIC ONCOLOGY*
Montz, F. J., Schlaerth, J. B., Berek, J. S.
1989; 35 (3): 338-340
- **Screening, diagnosis, and monitoring of gynecologic malignancies.** *Current opinion in oncology*
Montz, F. J., Berek, J. S.
1989; 1 (1): 75-81
- **SYNERGISTIC EFFECT OF COMBINED INTRAPERITONEAL CISPLATIN AND CYTOSINE-ARABINOSIDE IN A MURINE OVARIAN-CANCER MODEL** *OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Schink, J. C., Knox, R. M.
1989; 74 (4): 663-666
- **HUMAN NEUTROPHIL-MEDIATED LYSIS OF OVARIAN-CANCER CELLS** *BLOOD*
Lichtenstein, A., Seelig, M., Berek, J., ZIGHELBOIM, J.
1989; 74 (2): 805-809
- **CYTO-TOXIC AND CYTOSTATIC EFFECTS OF THE STREPTOCOCCAL PREPARATION OK-432 AND ITS SUBCELLULAR-FRACTIONS ON HUMAN OVARIAN TUMOR-CELLS** *CANCER*
Nio, Y., ZIGHELBOIM, J., Berek, J., Bonavida, B.
1989; 64 (2): 434-441
- **UTILIZATION OF A MURINE MODEL TO OPTIMIZE VOLUME AND DWELL TIME OF INTRAPERITONEAL CISPLATIN** *GYNECOLOGIC ONCOLOGY*
Pretorius, R. G., Eisenkop, S., Berek, J. S., Hacker, N. F., Ashikaga, T., Knox, R. M., Lagasse, L. D.
1989; 34 (1): 66-69
- **SYNCHRONOUS PRIMARY NEOPLASMS OF THE FEMALE REPRODUCTIVE-TRACT** *GYNECOLOGIC ONCOLOGY*
EISNER, R. F., Nieberg, R. K., Berek, J. S.
1989; 33 (3): 335-339
- **LYMPHOCYTE-ACTIVATION BY RECOMBINANT INTERLEUKIN-2 IN OVARIAN-CANCER PATIENTS** *OBSTETRICS AND GYNECOLOGY*
Boyer, P. J., Berek, J. S., ZIGHELBOIM, J.
1989; 73 (5): 793-797
- **VULVOVAGINAL MELANOMA - REPORT OF 7 CASES AND LITERATURE-REVIEW** *GYNECOLOGIC ONCOLOGY*
Brand, E., Fu, Y. S., Lagasse, L. D., Berek, J. S.
1989; 33 (1): 54-60
- **RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE PLUS CISPLATIN WITH OR WITHOUT DOXORUBICIN IN OVARIAN-CARCINOMA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY** *JOURNAL OF CLINICAL ONCOLOGY*
Omura, G. A., Bundy, B. N., Berek, J. S., Curry, S., Delgado, G., MORTEL, R.
1989; 7 (4): 457-465
- **PERITONEAL CYTOLOGY OF OVARIAN-CANCER PATIENTS RECEIVING INTRAPERITONEAL THERAPY - QUANTITATION OF MALIGNANT-CELLS AND RESPONSE** *OBSTETRICS AND GYNECOLOGY*
Sagae, S., Berek, J. S., Fu, Y. S., Chang, N., Dauplat, J., Hacker, N. F.
1988; 72 (5): 782-788
- **INTRAPERITONEAL ADMINISTRATION OF HUMAN RECOMBINANT INTERFERON-ALPHA IN PATIENTS WITH OVARIAN-CANCER - EFFECTS ON LYMPHOCYTE PHENOTYPE AND CYTO-TOXICITY** *CANCER RESEARCH*

- Lichtenstein, A., Spina, C., Berek, J. S., Jung, T., ZIGHELBOIM, J.
1988; 48 (20): 5853-5859
- **SENSITIVITY OF FRESH AND CULTURED OVARIAN TUMOR-CELLS TO TUMOR NECROSIS FACTOR, INTERFERON-ALPHA-2, AND OK-432** *CANCER IMMUNOLOGY IMMUNOTHERAPY*
Nio, Y., ZIGHELBOIM, J., Berek, J. S., Bonavida, B.
1988; 27 (3): 246-254
 - **PREOPERATIVE EVALUATION OF SERUM CA-125 LEVELS IN PREMENOPAUSAL AND POSTMENOPAUSAL PATIENTS WITH PELVIC MASSES - DISCRIMINATION OF BENIGN FROM MALIGNANT DISEASE** *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY*
Malkasian, G. D., Knapp, R. C., Lavin, P. T., Zurawski, V. R., Podratz, K. C., Stanhope, C. R., MORTEL, R., Berek, J. S., Bast, R. C., RITTS, R. E.
1988; 159 (2): 341-346
 - **IMMUNOLOGICAL CONTROL OF OVARIAN-CANCER** *NATURAL IMMUNITY AND CELL GROWTH REGULATION*
ZIGHELBOIM, J., Nio, Y., Berek, J. S., Bonavida, B.
1988; 7 (4): 216-225
 - **Uterine corpus and cervical cancer.** *Current problems in cancer*
Berek, J. S., Hacker, N. F., Hatch, K. D., Young, R. C.
1988; 12 (2): 61-131
 - **UTERINE CORPUS AND CERVICAL-CANCER** *CURRENT PROBLEMS IN CANCER*
Berek, J. S., Hatch, K. D., Hacker, N. F., Young, R. C.
1988; 12 (2): 65-129
 - **CONTROVERSIES IN THE MANAGEMENT OF CERVICAL ADENOCARCINOMA** *OBSTETRICS AND GYNECOLOGY*
Brand, E., Berek, J. S., Hacker, N. F.
1988; 71 (2): 261-269
 - **Minimal cervical cancer: definition and histology.** *Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer*
Fu, Y. S., Berek, J. S.
1988; 106: 47-56
 - **INTRAPERITONEAL CISPLATINUM AS SALVAGE THERAPY FOR REFRACTORY EPITHELIAL OVARIAN-CANCER** *OBSTETRICS AND GYNECOLOGY*
Hacker, N. F., Berek, J. S., Pretorius, R. G., Zuckerman, J., Eisenkop, S., Lagasse, L. D.
1987; 70 (5): 759-764
 - **RHABDOMYOSARCOMA OF THE UTERINE CERVIX - SARCOMA BOTRYOIDES** *CANCER*
Brand, E., Berek, J. S., Nieberg, R. K., Hacker, N. F.
1987; 60 (7): 1552-1560
 - **DISTANT METASTASES IN EPITHELIAL OVARIAN-CARCINOMA** *CANCER*
Dauplat, J., Hacker, N. F., Nieberg, R. K., Berek, J. S., Rose, T. P., Sagae, S.
1987; 60 (7): 1561-1566
 - **PROGNOSTIC-SIGNIFICANCE OF DNA PLOIDY AND MORPHOMETRIC ANALYSES OF ADENOCARCINOMA OF THE UTERINE CERVIX** *ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY*
Fu, Y. S., Hall, T. L., Berek, J. S., Hacker, N. F., Reagan, J. W.
1987; 9 (1): 17-24
 - **CA 125 FOR THE MONITORING OF OVARIAN-CARCINOMA DURING PRIMARY THERAPY** *OBSTETRICS AND GYNECOLOGY*
Lavin, P. T., Knapp, R. C., MALKASIAN, G., Whitney, C. W., BEREK, J. C., Bast, R. C.
1987; 69 (2): 223-227
 - **Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervix.** *Applied pathology*
Fu, Y. S., Berek, J. S., Hillborne, L. H.
1987; 5 (1): 47-56

- **INTRAPERITONEAL RECOMBINANT ALPHA-INTERFERON FOR SALVAGE IMMUNOTHERAPY IN STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY** *SEMINARS IN ONCOLOGY*
Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., Knox, R. M., Brady, J., Greene, T., Ettinger, L. M., Lagasse, L. D., Bonnem, E. M., Spiegel, R. J., ZIGHELBOIM, et al
1986; 13 (3): 61-71
- **HUMAN PAPILLOMAVIRUS DEOXYRIBONUCLEIC-ACID IN ADENOCARCINOMA AND ADENOSQUAMOUS CARCINOMA OF THE UTERINE CERVIX** *OBSTETRICS AND GYNECOLOGY*
Smotkin, D., Berek, J. S., Fu, Y. S., Hacker, N. F., Major, F. J., WETTSTEIN, F. O.
1986; 68 (2): 241-244
- **THE CA 125 ASSAY AS A PREDICTOR OF CLINICAL RECURRENCE IN EPITHELIAL OVARIAN-CANCER** *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY*
Niloff, J. M., Knapp, R. C., Lavin, P. T., Malkasian, G. D., Berek, J. S., MORTEL, R., Whitney, C., Zurawski, V. R., Bast, R. C.
1986; 155 (1): 56-60
- **CYTOREDUCTIVE SURGERY IN OVARIAN-CARCINOMA - FEASIBILITY AND MORBIDITY** *OBSTETRICS AND GYNECOLOGY*
Heintz, A. P., Hacker, N. F., Berek, J. S., Rose, T. P., Munoz, A. K., Lagasse, L. D.
1986; 67 (6): 783-788
- **CA-125 SERUM LEVELS CORRELATED WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS** *OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Knapp, R. C., Malkasian, G. D., Lavin, P. T., Whitney, C., Niloff, J. M., Bast, R. C.
1986; 67 (5): 685-689
- **NUCLEAR DEOXYRIBONUCLEIC-ACID HETEROGENEITY OF OVARIAN BORDERLINE MALIGNANT SEROUS TUMORS** *OBSTETRICS AND GYNECOLOGY*
Fu, Y. S., Ro, J., Reagan, J. W., Hall, T. L., Berek, J.
1986; 67 (4): 478-482
- **PHASE-II TRIAL OF CISPLATIN IN ADVANCED OR RECURRENT CANCER OF THE VAGINA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY** *GYNECOLOGIC ONCOLOGY*
Thigpen, J. T., Blessing, J. A., Homesley, H. D., Berek, J. S., Creasman, W. T.
1986; 23 (1): 101-104
- **ANTITUMOR AND IMMUNOLOGICAL EFFECTS OF A PYRIDINE-EXTRACTED FRACTION OF PROPIONIBACTERIUM-ACNES** *CANCER IMMUNOLOGY IMMUNOTHERAPY*
Lichtenstein, A., Berek, J.
1986; 22 (1): 24-30
- **Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer.** *Cancer treatment reviews*
Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., Knox, R. M., Brady, J., Greene, T., Ettinger, L. M., Lagasse, L. D.
1985; 12: 23-32
- **INTRAPERITONEAL RECOMBINANT INTERFERON-ALPHA-2 FOR SALVAGE IMMUNOTHERAPY IN PERSISTENT EPITHELIAL OVARIAN-CANCER** *CANCER TREATMENT REVIEWS*
Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., Knox, R. M., Brady, J., Greene, T., Ettinger, L. M., Lagasse, L. D., Bonnem, E. M., Spiegel, R. J., ZIGHELBOIM, et al
1985; 12: 23-32
- **SYNERGISTIC EFFECTS OF COMBINATION SEQUENTIAL IMMUNOTHERAPIES IN A MURINE OVARIAN-CANCER MODEL** *CANCER RESEARCH*
Berek, J. S., Lichtenstein, A. K., Knox, R. M., Jung, T. S., Rose, T. P., Cantrell, J. L., ZIGHELBOIM, J.
1985; 45 (9): 4215-4218
- **INTRAPERITONEAL IMMUNOTHERAPY OF EPITHELIAL OVARIAN-CARCINOMA WITH CORYNEBACTERIUM-PARVUM** *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Knapp, R. C., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., Obrist, R., Griffiths, C. T., Berkowitz, R. S., PARKER, L., ZIGHELBOIM, J., Bast, R. C.
1985; 152 (8): 1003-1010

- **WHOLE ABDOMINAL RADIATION AS SALVAGE THERAPY FOR EPITHELIAL OVARIAN-CANCER** *OBSTETRICS AND GYNECOLOGY*
Hacker, N. F., Berek, J. S., Burnison, C. M., Heintz, A. P., Juillard, G. J., Lagasse, L. D.
1985; 65 (1): 60-66
- **INTRAPERITONEAL RECOMBINANT ALPHA-INTERFERON FOR SALVAGE IMMUNOTHERAPY IN STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY** *CANCER RESEARCH*
Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., Knox, R. M., Brady, J., Greene, T., Ettinger, L. M., Lagasse, L. D., Bonnem, E. M., Spiegel, R. J., ZIGHELBOIM, et al
1985; 45 (9): 4447-4453
- **ADENOCARCINOMA OF THE UTERINE CERVIX - HISTOLOGIC VARIABLES ASSOCIATED WITH LYMPH-NODE METASTASIS AND SURVIVAL** *OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Hacker, N. F., Fu, Y. S., SOKALE, J. R., LEUCHTER, R. C., Lagasse, L. D.
1985; 65 (1): 46-52
- **NATURAL-KILLER INHIBITORY SUBSTANCE PRODUCED BY THE PERITONEAL-CELLS OF PATIENTS WITH OVARIAN-CANCER** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Lichtenstein, A. K., Berek, J., ZIGHELBOIM, J.
1985; 74 (2): 349-355
- **ROLE OF INFLAMMATORY NEUTROPHILS IN ANTITUMOR EFFECTS INDUCED BY INTRAPERITONEAL ADMINISTRATION OF CORYNEBACTERIUM-PARVUM IN MICE** *CANCER RESEARCH*
Lichtenstein, A. K., Berek, J., Kahle, J., ZIGHELBOIM, J.
1984; 44 (11): 5118-5123
- **SUCCESSFUL IMMUNOTHERAPY WITH INTRAPERITONEAL CORYNEBACTERIUM-PARVUM IN A MURINE OVARIAN-CANCER MODEL IS ASSOCIATED WITH THE RECRUITMENT OF TUMOR-LYTIC NEUTROPHILS INTO THE PERITONEAL-CAVITY** *JOURNAL OF IMMUNOLOGY*
Lichtenstein, A. K., Kahle, J., Berek, J., ZIGHELBOIM, J.
1984; 133 (1): 519-526
- **INDIVIDUALIZATION OF TREATMENT FOR STAGE-I SQUAMOUS-CELL VULVAR CARCINOMA** *OBSTETRICS AND GYNECOLOGY*
Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., Leuchter, R. S.
1984; 63 (2): 155-162
- **PREOPERATIVE RADIATION-THERAPY FOR LOCALLY ADVANCED VULVAR CANCER** *CANCER*
Hacker, N. F., Berek, J. S., Juillard, G. J., Lagasse, L. D.
1984; 54 (10): 2056-2061
- **IMMUNOTHERAPY WITH BIOCHEMICALLY DISSOCIATED FRACTIONS OF PROPIONIBACTERIUM ACNES IN A MURINE OVARIAN-CANCER MODEL** *CANCER RESEARCH*
Berek, J. S., Cantrell, J. L., Lichtenstein, A. K., Hacker, N. F., Knox, R. M., Nieberg, R. K., Poth, T., Elashoff, R. M., Lagasse, L. D., ZIGHELBOIM, J.
1984; 44 (5): 1871-1875
- **2ND-LOOK LAPAROTOMY IN STAGE-III EPITHELIAL OVARIAN-CANCER - CLINICAL-VARIABLES ASSOCIATED WITH DISEASE STATUS** *OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Hacker, N. F., Lagasse, L. D., Poth, T., Resnick, B., Nieberg, R. K.
1984; 64 (2): 207-212
- **RECTOSIGMOID COLECTOMY AND REANASTOMOSIS TO FACILITATE RESECTION OF PRIMARY AND RECURRENT GYNECOLOGIC CANCER** *OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Hacker, N. F., Lagasse, L. D.
1984; 64 (5): 715-720
- **VAGINAL RECONSTRUCTION PERFORMED SIMULTANEOUSLY WITH PELVIC EXENTERATION** *OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Hacker, N. F., Lagasse, L. D.
1984; 63 (3): 318-323
- **LYMPHOCYTE CYTO-TOXICITY IN THE PERITONEAL-CAVITY AND BLOOD OF PATIENTS WITH OVARIAN-CANCER** *OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Bast, R. C., Lichtenstein, A., Hacker, N. F., Spina, C. A., Lagasse, L. D., Knapp, R. C., ZIGHELBOIM, J.
1984; 64 (5): 708-714

- **ACTIVATION OF PERITONEAL LYMPHOCYTE CYTO-TOXICITY IN PATIENTS WITH OVARIAN-CANCER BY INTRAPERITONEAL TREATMENT WITH CORYNEBACTERIUM-PARVUM** *JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS*
Lichtenstein, A., Berek, J., Bast, R., Spina, C., Hacker, N., Knapp, R. C., ZIGHELBOIM, J.
1984; 3 (4): 371-378
- **ESTROGEN AND PROGESTERONE RECEPTORS IN OVARIAN NEOPLASMS** *GYNECOLOGIC ONCOLOGY*
Ford, L. C., Berek, J. S., Lagasse, L. D., Hacker, N. F., Heins, Y., Esmailian, F., Leuchter, R. S., DELANGE, R. J.
1983; 15 (3): 299-304
- **ESTROGEN AND PROGESTERONE-RECEPTOR SITES IN MALIGNANCIES OF THE UTERINE CERVIX, VAGINA, AND VULVA** *GYNECOLOGIC ONCOLOGY*
Ford, L. C., Berek, J. S., Lagasse, L. D., Hacker, N. F., HEINS, Y. L., DELANGE, R. J.
1983; 15 (1): 27-31
- **MANAGEMENT OF REGIONAL LYMPH-NODES AND THEIR PROGNOSTIC INFLUENCE IN VULVAR CANCER** *OBSTETRICS AND GYNECOLOGY*
Hacker, N. F., Berek, J. S., Lagasse, L. D., Leuchter, R. S., MOORE, J. G.
1983; 61 (4): 408-412
- **INTRAPERITONEAL IMMUNOTHERAPY OF HUMAN OVARIAN-CARCINOMA WITH CORYNEBACTERIUM-PARVUM** *CANCER RESEARCH*
Bast, R. C., Berek, J. S., Obrist, R., Griffiths, C. T., Berkowitz, R. S., Hacker, N. F., PARKER, L., Lagasse, L. D., Knapp, R. C.
1983; 43 (3): 1395-1401
- **SUPERFICIALLY INVASIVE VULVAR CANCER WITH NODAL METASTASES** *GYNECOLOGIC ONCOLOGY*
Hacker, N. F., Nieberg, R. K., Berek, J. S., Leuchter, R. S., LUCAS, W. E., Tamimi, H. K., Nolan, J. F., MOORE, J. G., Lagasse, L. D.
1983; 15 (1): 65-77
- **PRIMARY CYTOREDUCTIVE SURGERY FOR EPITHELIAL OVARIAN-CANCER** *OBSTETRICS AND GYNECOLOGY*
Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., Elashoff, R. M.
1983; 61 (4): 413-420
- **SURVIVAL OF PATIENTS FOLLOWING SECONDARY CYTOREDUCTIVE SURGERY IN OVARIAN-CANCER** *OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Hacker, N. F., Lagasse, L. D., Nieberg, R. K., Elashoff, R. M.
1983; 61 (2): 189-193
- **DELAYED VAGINAL RECONSTRUCTION IN THE FIBROTIC PELVIS FOLLOWING RADIATION OR PREVIOUS RECONSTRUCTION** *OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Hacker, N. F., Lagasse, L. D., Smith, M. L.
1983; 61 (6): 743-748
- **MICROINVASIVE CARCINOMA OF THE VULVA** *OBSTETRICS AND GYNECOLOGY*
Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K.
1983; 62 (1): 134-135
- **LAPAROSCOPY IN THE MANAGEMENT OF PATIENTS WITH OVARIAN-CARCINOMA** *CLINICS IN OBSTETRICS AND GYNAECOLOGY*
Berek, J. S., Hacker, N. F.
1983; 10 (2): 213-222
- **PHARMACOKINETICS OF IP CISPLATIN IN REFRACTORY OVARIAN-CARCINOMA** *CANCER TREATMENT REPORTS*
Pretorius, R. G., Hacker, N. F., Berek, J. S., Ford, L. C., Hoeschele, J. D., Butler, T. A., Lagasse, L. D.
1983; 67 (12): 1085-1092
- **MANAGEMENT OF POST-EXENTERATION PERINEAL HERNIAS BY MYOCUTANEOUS AXIAL FLAPS** *GYNECOLOGIC ONCOLOGY*
Leuchter, R. S., Lagasse, L. D., Hacker, N. F., Berek, J. S.
1982; 14 (1): 15-22
- **RECENT PROGRESS IN THE TREATMENT OF EPITHELIAL OVARIAN MALIGNANCY** *WESTERN JOURNAL OF MEDICINE*
Berek, J. S., Hacker, N. F., Lagasse, L. D.
1982; 137 (4): 273-277

- **PRIMARY-CARCINOMA OF THE BARTHOLIN GLAND - A REPORT OF 14 CASES AND REVIEW OF THE LITERATURE** *OBSTETRICS AND GYNECOLOGY*
Leuchter, R. S., Hacker, N. F., Voet, R. L., Berek, J. S., Townsend, D. E., Lagasse, L. D.
1982; 60 (3): 361-368
- **LOWER URINARY-TRACT RESECTION AS PART OF CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER** *GYNECOLOGIC ONCOLOGY*
Berek, J. S., Hacker, N. F., Lagasse, L. D., Leuchter, R. S.
1982; 13 (1): 87-92
- **LEVATOR ANI TRANSPOSITION FOR ANAL INCOMPETENCE SECONDARY TO SPHINCTER DAMAGE** *OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Lagasse, L. D., Hacker, N. F., Leuchter, R. S.
1982; 59 (1): 108-112
- **CARCINOMA OF THE CERVIX ASSOCIATED WITH PREGNANCY** *OBSTETRICS AND GYNECOLOGY*
Hacker, N. F., Berek, J. S., Lagasse, L. D., Charles, E. H., SAVAGE, E. W., MOORE, J. G.
1982; 59 (6): 735-747
- **RADICAL VULVECTOMY AND BILATERAL INGUINAL LYMPHADENECTOMY THROUGH SEPARATE GROIN INCISIONS** *OBSTETRICS AND GYNECOLOGY*
Hacker, N. F., Leuchter, R. S., Berek, J. S., CASTALDO, T. W., Lagasse, L. D.
1981; 58 (5): 574-579
- **ADENOCARCINOMA OF THE UTERINE CERVIX** *CANCER*
Berek, J. S., CASTALDO, T. W., Hacker, N. F., PETRILLI, E. S., Lagasse, L. D., MOORE, J. G.
1981; 48 (12): 2734-2741
- **LAPAROSCOPY FOR 2ND-LOOK EVALUATION IN OVARIAN-CANCER** *OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Griffiths, C. T., Leventhal, J. M.
1981; 58 (2): 192-198
- **PERINATAL-MORTALITY IN TERM AND POST-TERM BIRTHS** *OBSTETRICS AND GYNECOLOGY*
Stubblefield, P. G., Berek, J. S.
1980; 56 (6): 676-682
- **MASSIVE EXUDATIVE ASCITES PRODUCED FROM A TUBAL PSEUDOCYST IN CHRONIC PELVIC INFLAMMATORY DISEASE** *OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Darney, P. D.
1979; 54 (4): 490-492
- **ANATOMIC AND CLINICAL CORRELATES OF UTERINE PERFORATION** *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY*
Berek, J. S., Stubblefield, P. G.
1979; 135 (2): 181-184
- **EVALUATION OF A BALLOON DILATOR BEFORE 2ND-TRIMESTER ABORTION BY VACUUM CURETTAGE** *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY*
Stubblefield, P. G., Frederiksen, M. C., Berek, J. S., GATTER, M. A., Kayman, D. J., BORTEN, M.
1979; 135 (2): 199-201